Drug Approval | June 01, 2026
Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
The therapy also delivered significant improvements in key liver enzyme markers
The therapy also delivered significant improvements in key liver enzyme markers
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
